Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123437392 | 12343739 | 2 | F | 20160909 | 20160507 | 20160914 | EXP | PHEH2016US011290 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160914 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123437392 | 12343739 | 1 | PS | DIOVAN | VALSARTAN | 1 | Oral | 160 MG, QD | U | 20665 | 160 | MG | QD | ||||||
| 123437392 | 12343739 | 2 | SS | DIOVAN | VALSARTAN | 1 | Unknown | UNK | U | UNKNOWN | 20665 | ||||||||
| 123437392 | 12343739 | 3 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123437392 | 12343739 | 1 | Product used for unknown indication |
| 123437392 | 12343739 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123437392 | 12343739 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123437392 | 12343739 | Feeling abnormal | |
| 123437392 | 12343739 | Hypertension | |
| 123437392 | 12343739 | Inappropriate schedule of drug administration | |
| 123437392 | 12343739 | Palpitations | |
| 123437392 | 12343739 | Product colour issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |